What they say: Introduction:
A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July 2014 issue of the journal “EMBO”, by Prof Sinclair, North BJ, and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Lifespan extension therapy: Nateglinide, an anti- hyperglycemic medication, increases life span via up-regulation of its target gene BubR1
What is known?
Nateglinide is an anti-hyperglycemic medication prescribed to treat TIIDM. However, the mechanism of action is far from clear. I had published earlier that Nateglinide may improve insulin sensitivity, promote resistance to bone, immune and motor dysfunction and extend lifespan through down regulation of p70 S6 Kinase.
From Research Findings to Therapeutic Opportunity:
This study suggests, for the first time, a role for Nateglinide in lifespan extension therapy. Nateglinide, by increasing the expression of its target gene, it may: (a) increase the expression of BuBR1; and (b) decrease the expression of p70 S6 Kinase.
[easy_payment currency=”USD”]
Figure 1. Nateglinide, an antihyperglycemic medication, may extend mammalian life span via up regulation of BuBR1 and down regulation of p70 S6 Kinase
Thereby, it may: (1) delay diseases of aging; (2) slow down aging; and (3) prolong median life span. Thus, pharmacological formulations encompassing “Nateglinide or its analogues, either alone or in combination with any drug“ may be used to extend the lifespan of an individual (fig. 1).
Details on the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D.
Amount: $100#
Undisclosed mechanistic information: How Nateglinide increases the expression of BubR1 and extends mammalian life-span
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
# Research cooperation
References:
Web: http://genomediscovery.org or http://newbioideas.com
Citation: Boominathan, L., Lifespan extension therapy: Nateglinide, an anti- hyperglycemic medication, increases life span via up-regulation of its target gene BubR1, 8/October/2016, 7.01 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at admin@genomediscovery.org